RSCM
ALXN

Rock Springs Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Rock Springs Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-306,750
Closed -$47.9M – 169
2020
Q4 		$47.9M Buy
306,750
+81,750
+36% +$10.5M 1.02% 30
2020
Q3 		$25.7M Buy
225,000
+41,500
+23% +$4.48M 0.65% 49
2020
Q2 		$20.6M Buy
+183,500
New +$19.5M 0.56% 59
2019
Q3 		– Sell
-242,500
Closed -$31.8M – 144
2019
Q2 		$31.8M Hold
242,500
– – 1.15% 25
2019
Q1 		$32.8M Hold
242,500
– – 1.26% 21
2018
Q4 		$23.6M Sell
242,500
-57,500
-19% -$6.8M 1.11% 26
2018
Q3 		$41.7M Sell
300,000
-192,500
-39% -$24.1M 1.51% 14
2018
Q2 		$61.1M Buy
492,500
+7,500
+2% +$877K 2.35% 6
2018
Q1 		$54.1M Buy
485,000
+5,000
+1% +$598K 2.31% 4
2017
Q4 		$57.4M Buy
480,000
+17,000
+4% +$2.07M 2.6% 4
2017
Q3 		$65M Hold
463,000
– – 3% 2
2017
Q2 		$56.3M Buy
463,000
+6,100
+1% +$710K 2.84% 5
2017
Q1 		$55.4M Sell
456,900
-8,100
-2% -$1.04M 3.2% 3
2016
Q4 		$56.9M Buy
465,000
+197,750
+74% +$24.2M 3.81% 2
2016
Q3 		$32.7M Buy
267,250
+31,750
+13% +$4.09M 2.05% 11
2016
Q2 		$27.5M Buy
235,500
+7,750
+3% +$1.1M 2.04% 12
2016
Q1 		$31.7M Buy
227,750
+34,750
+18% +$5.1M 2.66% 6
2015
Q4 		$36.8M Buy
193,000
+21,000
+12% +$3.67M 2.79% 4
2015
Q3 		$26.9M Buy
172,000
+17,500
+11% +$3.19M 2.18% 8
2015
Q2 		$27.9M Buy
154,500
+46,250
+43% +$7.98M 2.04% 11
2015
Q1 		$18.8M Buy
108,250
+15,750
+17% +$2.85M 1.75% 16
2014
Q4 		$17.1M Buy
92,500
+2,750
+3% +$510K 2% 15
2014
Q3 		$14.9M Buy
89,750
+4,000
+5% +$657K 2.3% 11
2014
Q2 		$13.4M Buy
85,750
+37,250
+77% +$5.88M 2.4% 12
2014
Q1 		$7.38M Sell
48,500
-2,500
-5% -$398K 1.7% 21
2013
Q4 		$6.79M Buy
+51,000
New +$6.12M 2.42% 14

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rock Springs Capital Management's ALXN Position: Q1 2021 in Review

Rock Springs Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 306,750 shares — an estimated $47.9M sold.

Rock Springs Capital Management first reported a position in ALXN in Q4 2013 and held it in 26 quarters. The position peaked at $65M in Q3 2017. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Rock Springs Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Rock Springs Capital Management sold 306,750 Alexion Pharmaceuticals shares in Q1 2021, an estimated $47.9M.
  • Rock Springs Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 26 quarters.
  • Rock Springs Capital Management's Alexion Pharmaceuticals position peaked at $65M in Q3 2017.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Rock Springs Capital Management's 13F filing for Q1 2021, filed 17 May 2021.